Abbott Laboratories (NYSE: ABT) stock closed at 101.26 per share at the end of the most recent trading day (a 2.2% change compared to the prior day closing price) with a volume of 6.17M shares and market capitalization of 175.98B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 109000 people. Abbott Laboratories CEO is Robert B. Ford.

The one-year performance of Abbott Laboratories stock is -16.29%, while year-to-date (YTD) performance is -7.77%. ABT stock has a five-year performance of 68.99%. Its 52-week range is between 93.25 and 124.36, which gives ABT stock a 52-week price range ratio of 25.75%

Abbott Laboratories currently has a PE ratio of 25.40, a price-to-book (PB) ratio of 5.49, a price-to-sale (PS) ratio of 5.83, a price to cashflow ratio of 19.30, a PEG ratio of 2.32, a ROA of 11.66%, a ROC of 15.73% and a ROE of 24.34%. The company’s profit margin is 17.58%, its EBITDA margin is 29.30%, and its revenue ttm is $33.56 Billion , which makes it $19.25 revenue per share.

Of the last four earnings reports from Abbott Laboratories, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.98 for the next earnings report. Abbott Laboratories’s next earnings report date is 19th Apr 2023.

The consensus rating of Wall Street analysts for Abbott Laboratories is Strong Buy (1.41), with a target price of $118.53, which is +17.06% compared to the current price. The earnings rating for Abbott Laboratories stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Abbott Laboratories has a dividend yield of 1.82% with a dividend per share of $2.04 and a payout ratio of 45.00%.

Abbott Laboratories has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.22, ATR14 : 1.87, CCI20 : 134.49, Chaikin Money Flow : -0.03, MACD : -1.23, Money Flow Index : 62.57, ROC : 3.54, RSI : 53.72, STOCH (14,3) : 96.98, STOCH RSI : 1.00, UO : 59.79, Williams %R : -3.02), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Abbott Laboratories in the last 12-months were: Andrea F. Wainer (Sold 679 shares of value $68 375 ), Daniel Gesua Sive Salvadori (Sold 1 085 shares of value $109 260 ), Daniel J. Starks (Sold 150 000 shares of value $15 990 972 ), Fernando Mateus (Sold 2 457 shares of value $267 943 ), Gregory A. Ahlberg (Sold 1 317 shares of value $132 622 ), Hubert L. Allen (Sold 1 069 shares of value $107 648 ), Jared L. Watkin (Sold 1 198 shares of value $120 639 ), John F. Ginascol (Sold 11 943 shares of value $1 330 480 ), Joseph J. Manning (Option Excercise at a value of $2 043 110), Joseph J. Manning (Sold 51 245 shares of value $5 421 781 ), Julie L. Tyler (Sold 1 038 shares of value $107 310 ), Lisa D. Earnhardt (Sold 943 shares of value $94 960 ), Mary K. Moreland (Sold 717 shares of value $72 252 ), Michael D. Dale (Sold 1 209 shares of value $121 746 ), Randel W. Woodgrift (Option Excercise at a value of $1 065 600), Randel W. Woodgrift (Sold 25 032 shares of value $2 816 025 ), Robert B. Ford (Option Excercise at a value of $4 121 870), Robert B. Ford (Sold 102 425 shares of value $10 765 154 ), Robert E. Funck (Sold 1 264 shares of value $127 285 ), Sammy Karam (Sold 4 200 shares of value $456 750 )